These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34283204)

  • 1. Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
    van Dorst DCH; van Doorn L; Mirabito Colafella KM; Manintveld OC; Hassing HC; Danser AHJ; Mathijssen RHJ; Versmissen J
    Clin Sci (Lond); 2021 Jul; 135(14):1649-1668. PubMed ID: 34283204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone.
    Crocetto F; Ferro M; Buonerba C; Bardi L; Dolce P; Scafuri L; Mirto BF; Verde A; Sciarra A; Barone B; Calogero A; Sagnelli C; Busetto GM; Del Giudice F; Cilio S; Sonpavde G; Di Trolio R; Della Ratta GL; Barbato G; Di Lorenzo G
    Crit Rev Oncol Hematol; 2023 Aug; 188():104059. PubMed ID: 37353178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular toxicity associated with anti-angiogenic drugs.
    Neves KB; Montezano AC; Lang NN; Touyz RM
    Clin Sci (Lond); 2020 Sep; 134(18):2503-2520. PubMed ID: 32990313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price.
    Achim A; Liblik K; Gevaert S
    Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxic effects of angiogenesis inhibitors.
    Dobbin SJH; Petrie MC; Myles RC; Touyz RM; Lang NN
    Clin Sci (Lond); 2021 Jan; 135(1):71-100. PubMed ID: 33404052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Call for attention to the scientific issues in cardiovascular adverse effects associated with immune checkpoint inhibitors].
    Zhang ZR
    Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(42):3328-3331. PubMed ID: 37963733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
    Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN
    Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.
    Liu Q; Yu Y; Lin J; Wang Y; Ai L; Li Q; Wu W; Jin H; Li S; Liu M; Yu S; Liu T
    Eur J Cancer; 2021 Nov; 157():10-20. PubMed ID: 34464781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity danger in immunotherapy.
    Jagielska B; Ozdowska P; Gepner K; Kubala S; Siedlecki JA; Sarnowski TJ; Sarnowska E
    IUBMB Life; 2020 Jun; 72(6):1160-1167. PubMed ID: 32359132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall.
    Piras L; Zuccanti M; Russo P; Riccio F; Agresti A; Lustri C; Dardani D; Ferrera A; Fiorentini V; Tocci G; Tini Melato G; Volpe M; Barbato E; Battistoni A
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
    Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
    J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
    Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
    Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Therapeutics-related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation.
    Peleg Hasson S; Arnold J; Merdler I; Sivan A; Shamai S; Geva R; Merimsky O; Shachar E; Waissengrin B; Moshkovits Y; Arbel Y; Topilsky Y; Rozenbaum Z; Wolf I; Laufer-Perl M
    J Immunother; 2021 Jun; 44(5):179-184. PubMed ID: 33950028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors.
    Lessomo FYN; Mandizadza OO; Mukuka C; Wang ZQ
    Eur J Med Res; 2023 Nov; 28(1):495. PubMed ID: 37941006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.
    Pirozzi F; Poto R; Aran L; Cuomo A; Galdiero MR; Spadaro G; Abete P; Bonaduce D; Marone G; Tocchetti CG; Varricchi G; Mercurio V
    Curr Oncol Rep; 2021 Jan; 23(2):13. PubMed ID: 33415405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular adverse events associated with immune checkpoint inhibitors: a meta-analysis.
    Li X; Li D
    Front Immunol; 2024; 15():1394123. PubMed ID: 38979409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
    Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
    Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.